Oruka Therapeutics, Inc.

NasdaqGM:ORKA Stock Report

Market Cap: US$3.7b

Oruka Therapeutics Management

Management criteria checks 1/4

Oruka Therapeutics' CEO is Lawrence Klein, appointed in Feb 2024, has a tenure of 2.25 years. total yearly compensation is $3.36M, comprised of 18.6% salary and 81.4% bonuses, including company stock and options. directly owns 1.54% of the company’s shares, worth $56.20M. The average tenure of the management team and the board of directors is 2 years and 2.3 years respectively.

Key information

Lawrence Klein

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage18.59%
CEO tenure2.3yrs
CEO ownership1.5%
Management average tenure2yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 27

Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001

Summary Oruka Therapeutics (ORKA) earns a "Strong Buy" rating after positive phase 2a interim results for ORKA-001 in moderate-to-severe plaque psoriasis. ORKA-001’s half-life extension technology targets once-yearly dosing, aiming for best-in-class efficacy and competitive differentiation in a crowded biologics market. Key near-term catalysts include longer-term phase 2a follow-up data in H2 2026 and phase 2b EVERLAST-B dose-finding results in 2027 for ORKA-001. ORKA maintains robust liquidity [$479.7M cash], but may need to raise capital within 12 months to sustain operations and advance its pipeline. Read the full article on Seeking Alpha
Analysis Article • Jul 15

We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Apr 01

We're Hopeful That Oruka Therapeutics (NASDAQ:ORKA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Lawrence Klein's remuneration changed compared to Oruka Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$94m

Dec 31 2025US$3mUS$624k

-US$84m

Sep 30 2025n/an/a

-US$84m

Jun 30 2025n/an/a

-US$77m

Mar 31 2025n/an/a

-US$80m

Dec 31 2024US$521kUS$203k

-US$71m

Compensation vs Market: Lawrence's total compensation ($USD3.36M) is below average for companies of similar size in the US market ($USD7.02M).

Compensation vs Earnings: Lawrence's compensation has increased whilst the company is unprofitable.

CEO

Lawrence Klein (42 yo)

2.3yrs
Tenure
US$3,356,050
Compensation

Dr. Lawrence Otto Klein, Ph D, is an Independent Director of Jade Biosciences, Inc. since July 2024. Dr. Klein is Chief Executive Officer of Oruka Therapeutics and serves as its Director.Dr. Klein served...

Leadership Team

NamePositionTenureCompensationOwnership
Lawrence Klein
President2.3yrsUS$3.36m1.54%
$ 56.2m
Paul Quinlan
General Counsel & Secretary1.8yrsUS$2.34m0.053%
$ 1.9m
Joana Goncalves
Chief Medical Officer1.8yrsUS$2.34m0.055%
$ 2.0m
Arjun Agarwal
Senior VP of Finance & Treasurer2.2yrsno data0.027%
$ 994.3k
Laura Sandler
Chief Operating Officer2.2yrsno data0.39%
$ 14.4m
Alan Lada
VP of IR & Capital Marketsno datano datano data
Christopher Finch
Senior VP and Head of Business Development & Strategyless than a yearno datano data
Rajiv Panwar
Senior VP and Head of Chemistryno datano datano data
2.0yrs
Average Tenure
49yo
Average Age

Experienced Management: ORKA's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Lawrence Klein
President2.3yrsUS$3.36m1.54%
$ 56.2m
Kristine Ball
Independent Director2yrsUS$213.07kno data
Samarth Kulkarni
Independent Chairman of Board2.3yrsUS$234.07k0%
$ 0
Peter Harwin
Independent Director2.3yrsUS$209.07k0%
$ 0
Christopher Martin
Independent Directorless than a yearUS$803.95kno data
Carl Dambkowski
Independent Director2.3yrsUS$200.57k0.19%
$ 7.1m
Andrew Blauvelt
Chairman of Scientific Advisory Boardno datano datano data
2.3yrs
Average Tenure
44.5yo
Average Age

Experienced Board: ORKA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 17:17
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oruka Therapeutics, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Julian HarrisonBTIG
Yatin SunejaGuggenheim Securities, LLC